Roots Analysis has done a detailed study on STING
Pathway Targeting Therapeutics and Technologies, 2020-2030, covering key
aspects of the industry and identifying future growth opportunities.
To order this 310+ page report, which features 150+ figures
and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html
Key Market Insights
§
§
§
§
§
§
§
§
§
§
For more information, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html
Table of Contents
1. PREFACE
1.1. Scope
of the Report
1.2. Research
Methodology
1.3. Key
Questions Answered
1.4. Chapter
Outlines
2. EXECUTIVE
SUMMARY
3.1. Stimulator of Interferon Genes
(STING) Pathway
3.2. STING Signaling
3.2.1. Relevance in Cancer
3.2.2. Relevance in Autoimmune Diseases
3.2.3. Relevance in Antimicrobial Host
Defense
3.3. STING Pathway Modulators
3.3.1. STING Agonists
3.3.2. STING Antagonists
3.3.3. STING Activating Drug Delivery
Systems
3.3.4. Indirect STING Activating Therapies
3.4. Key Variants of STING
3.5. Non-immunological Functions of the
STING Pathway
3.6. Concluding Remarks
4. STING PATHWAY TARGETING
THERAPEUTICS: CURRENT MARKET LANDSCAPE
4.1. Chapter
Overview
4.2. STING
Pathway Targeting Therapeutics: Development Pipeline
4.2.1. Analysis
by Type of STING Modulator
4.2.2. Analysis
by Type of Molecule
4.2.3. Analysis
by Phase of Development
4.2.4. Analysis
by Therapeutic Area
4.2.5. Analysis
by Type of Therapy
4.2.6. Analysis
by Route of Administration
4.2.7. Analysis
by Line of Treatment
4.3. STING
Pathway Targeting Therapeutics: Developer Landscape
4.3.1. Analysis
by Year of Establishment
4.3.2. Analysis
by Company Size
4.3.3. Analysis
by Geography
4.3.4. Most
Active Players
4.4. STING
Pathway Targeting Therapeutics: List of Clinical Trials
4.4.1. Analysis
by Trial Recruitment Status
4.4.2. Analysis
by Study Design
4.4.3. Analysis
by Key Clinical Endpoints
5. STING PATHWAY TARGETING
TECHNOLOGIES: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. STING Pathway Targeting
Technologies: List of Technology Developers
5.2.1. Analysis by Type of Modulator
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Year of Establishment
5.2.4. Analysis by Company Size
5.2.5. Analysis by Geography
6. COMPANY PROFILES
6.1. Chapter
Overview
6.2 STING
Agonist Developers
6.2.1. Aduro
Biotech
6.2.1.1. Company
Overview
6.2.1.2. Financial
Information
6.2.1.3. Product
Description: ADU-S100 (MIW815)
6.2.1.4. Recent
Developments and Future Outlook
6.2.2. Bristol-Myers
Squibb
6.2.2.1. Company
Overview
6.2.2.2. Financial
Information
6.2.2.3. Product
Description: BMS-986301
6.2.2.4. Recent
Developments and Future Outlook
6.2.3. Eisai
6.2.3.1. Company
Overview
6.2.3.2. Financial
Information
6.2.3.3. Product
Description: E7766
6.2.3.4. Recent
Developments and Future Outlook
6.2.4 GlaxoSmithKline
6.2.4.1. Company
Overview
6.2.4.2. Financial
Information
6.2.4.3. Product
Description: GSK3745417
6.2.4.4. Recent
Developments and Future Outlook
6.2.5. ImmuneSensor
Therapeutics
6.2.5.1. Company
Overview
6.2.5.2. Product
Description: IMSA101
6.2.6. Merck
6.2.6.1. Company
Overview
6.2.6.2. Financial
Information
6.2.6.3. Product
Description: MK-1454 and MK-2118
6.2.6.4. Recent
Developments and Future Outlook
6.2.7. Noxopharm
6.2.7.1. Company
Overview
6.2.7.2. Product
Description: NOX66
6.2.7.3. Recent
Developments and Future Outlook
6.2.8. Spring
Bank Pharmaceuticals
6.2.8.1. Company
Overview
6.2.8.2. Financial
Information
6.2.8.3. Product
Description: SB 11285
6.2.8.4. Recent
Developments and Future Outlook
6.2.9. Synlogic
6.2.9.1. Company
Overview
6.2.9.2. Financial
Information
6.2.9.3. Product
Description: SYNB1891
6.2.9.4. Recent
Developments and Future Outlook
6.3. STING
Antagonist Developers
6.3.1 Avammune
Therapeutics
6.3.2. Curadev
6.3.3 ImmuneSensor
Therapeutics
6.3.4. Nimbus
Therapeutics
6.3.5. Sirenas
6.3.6. Spring
Bank Pharmaceuticals
6.3.7. STINGINN
6.3.8. STipe
Therapeutics
7 ACADEMIC GRANT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. STING Pathway Targeting
Therapeutics: List of Academic Grants
7.3.1. Analysis by Number of Grants
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Mechanism
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Grant Activity Code
7.3.8. Analysis by Funding Institutes
7.3.9. Analysis by Type of Recipient
Organization
7.3.10 Regional Distribution of Grant
Recipients
7.3.11 Most Popular Recipient Organizations:
Analysis by Number of Grants and Amount Invested
7.3.12. Prominent Project Leaders: Analysis by
Number of Grants
7.3.13 Analysis by Support Year and Amount
Awarded
7.3.14. Analysis by Study Section
7.4. Grant Attractiveness Analysis
8 STING RELATED INITIATIVES OF
BIG PHARMACEUTICALS PLAYERS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Initiatives Undertaken by Big
Pharma Players
8.3.1. Analysis by Portfolio Diversity
8.3.2. Analysis by Type of Molecule
8.3.3. Analysis by Phase of Development
8.3.4. Analysis by Therapeutic Area
8.3.5. Analysis by Type of Therapy
8.3.6. Analysis by Route of Administration
8.4. Benchmarking Big Pharma Players
8.4.1 Spider Web Analysis: AbbVie
8.4.2. Spider Web Analysis: Bayer
8.4.3. Spider Web Analysis: Bristol-Myers
Squibb
8.4.4. Spider Web Analysis: Celgene
8.4.5. Spider Web Analysis: Eisai
8.4.6. Spider Web Analysis: Eli Lily
8.4.7. Spider Web Analysis: Genentech
8.4.8. Spider Web Analysis: GlaxoSmithKline
8.4.9. Spider Web Analysis: Merck
8.4.10. Spider Web Analysis: Novartis
8.4.11. Spider Web Analysis: Novo Nordisk
8.4.12. Spider Web Analysis: Pfizer
8.4.13. Spider Web Analysis: Roche
8.4.14. Spider Web Analysis: Takeda
Pharmaceuticals
9 START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Benchmarking of Start-ups
9.3.1. Analysis by Portfolio Diversity
9.3.2. Analysis by Type of Molecule
9.3.3. Analysis by Phase of Development
9.3.4 Analysis by Therapeutic Area
9.3.5. Analysis by Funding Amount
9.3.6. Analysis by Number of Investors
9.3.7. Analysis by Type of Funding
9.3.8. Analysis by Partnership Activity
9.3.9. Analysis by Other Parameters
9.3.10. Analysis by Location of Headquarters
9.3.11. Start-up Health Indexing: Roots
Analysis Perspective
10 PUBLICATION ANALYSIS
10.1. Chapter
Overview
10.2. Scope
and Methodology
10.3. STING
Pathway Targeting Therapeutics: Recent Publications
10.3.1. Analysis
by Type of Publication
10.3.2. Analysis
by Type of Publication and Year
10.3.3. Analysis
by Study Objective
10.3.4. Analysis
by Popular Keywords
10.3.5. Analysis
by Type of STING Modulator
10.3.6. Analysis
by Target Pathway
10.3.7. Analysis
by Therapeutic Area
10.3.8. Analysis
by Type of STING Modulator and Therapeutic Area
10.3.9 Analysis by Type of Publisher
10.3.10. Leading Players: Analysis by Number of
Publications
10.3.11. Leading Players: Geographical Analysis by
Number of Publications
10.3.12. Analysis
by First Author Organization
10.3.13. Key
Journals: Analysis by Number of Publications
11 PARTNERSHIPS
AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. STING Pathway Targeting Therapeutics:
Recent Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3 Analysis by Type of STING Modulator
11.3.4. Analysis by Therapeutic Area
11.3.5. Analysis by Technology Platform
11.3.6. Most Active Players: Analysis by Number
of Partnerships
11.3.7. Geographical Analysis
11.3.7.1 Most Active Players: Analysis by Number
of partnerships
11.3.7.2. Intercontinental and Intracontinental
Agreements
12. FUNDING
AND INVESTMENT ANALYSIS
12.1. Chapter
Overview
12.2. Types
of Funding
12.3. STING
Pathway Targeting Therapeutics: Recent Funding Instances
12.3.1. Analysis
by Number of Funding Instances
12.3.2. Analysis
by Amount Invested
12.3.3. Analysis
by Type of Funding
12.3.4. Analysis
by Type of STING Modulator
12.3.6. Analysis
by Therapeutic Area
12.3.6 Analysis
by Amount Invested and Type of STING Technology Platform
12.3.7. Most
Active Players: Analysis by Number of Funding Instances
12.3.8. Most
Active Investors: Analysis by Number of Funding Instances
12.3.9. Geographical
Analysis by Amount Invested
12.4. Concluding
Remarks
13. MARKET SIZING AND OPPORTUNITY
ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast
Methodology
13.3. Global STING Pathway Targeting
Technologies Market, 2020-2030
13.3.1. STING Pathway Targeting Technologies
Market by Upfront Payments, 2020-2030
13.3.2. STING Pathway Targeting Technologies
Market by Milestone Payments, 2020-2030
13.3.3. STING Pathway Targeting Technologies
Market: Distribution by Type of STING Modulator
13.3.3.1. STING Pathway Targeting Technologies
Market for Agonist, 2020-2030
13.3.3.2. STING Pathway Targeting Technologies
Market for Antagonist, 2020-2030
13.3.4. STING Pathway Targeting Technologies
Market: Distribution by Therapeutic Area
13.3.4.1. STING Pathway Targeting Technologies
Market for Oncological Disorders, 2020-2030
13.3.4.2. STING Pathway Targeting Technologies
Market for Inflammatory Disorders, 2020-2030
13.3.4.3. STING Pathway Targeting Technologies
Market for Infectious Diseases, 2020-2030
13.3.4.4. STING Pathway Targeting Technologies
Market for Other Therapeutic Areas, 2020-2030
13.3.5. STING Pathway Targeting Technologies
Market: Distribution by Route of Administration
13.3.5.1. STING Pathway Targeting Technologies
Market for Intratumoral Route, 2020-2030
13.3.5.2. STING Pathway Targeting Technologies
Market for Intravenous Route, 2020-2030
13.3.5.3. STING Pathway Targeting Technologies
Market for Oral Route, 2020-2030
13.3.5.4. STING Pathway Targeting Technologies
Market for Subcutaneous Route, 2020-2030
13.3.5.5. STING Pathway Targeting Technologies
Market for Other Routes, 2020-2030
13.3.6. STING Pathway Targeting Technologies
Market: Distribution by Type of Molecule
13.3.6.1. STING Pathway Targeting Technologies
Market for Non-Nucleotide, 2020-2030
13.3.6.2. STING Pathway Targeting Technologies
Market for Cyclic Dinucleotide, 2020-2030
13.3.6.3. STING Pathway Targeting Technologies
Market for Live Biotherapeutics, 2020-2030
13.3.6.4. STING Pathway Targeting Technologies
Market for Oncolytic Viruses, 2020-2030
13.3.6.5. STING Pathway Targeting Technologies
Market for Synthetic Peptides, 2020-2030
13.3.6.6. STING Pathway Targeting Technologies
Market for Other Molecules, 2020-2030
13.3.7. STING Pathway Targeting Technologies
Market: Distribution by Geography
13.3.7.1. STING Pathway Targeting Technologies
Market in North America, 2020-2030
13.3.7.2. STING Pathway Targeting Technologies
Market in Europe, 2020-2030
13.3.7.3. STING Pathway Targeting Technologies
Market in Asia-Pacific, 2020-2030
15. CONCLUDING REMARKS
15.1. Chapter Overview
15.2. Key Takeaways
16. APPENDIX
1: TABULATED DATA
17. APPENDIX
2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415